Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse

Phase 1 Completed 15 enrolled Innate Pharma

NaSingle-groupOpen-labelTreatment

Summary

The primary objective of the clinical study is to evaluate, in patients who experience a first or second relapse of their multiple myeloma, the safety of escalating doses of IPH2101 combined with lenalidomide

Timeline

Start: 2010-09
Primary completion: 2013-12
Completion: 2014-02

Publications

Benson DM Jr, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA. A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2015 Sep 15;21(18):4055-61. doi: 10.1158/1078-0432.CCR-15-0304. Epub 2015 May 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IPH2101	Monoclonal antibody	0.2 mg/kg	Intravenous
Subject	IPH2101	Monoclonal antibody	1 mg/kg	Intravenous
Subject	IPH2101	Monoclonal antibody	2 mg/kg	Intravenous
Subject	Lenalidomide	Other / unclassified	10 mg	Oral
Subject	Lenalidomide	Other / unclassified	25 mg	Oral

Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse

Summary

Timeline

Publications

Drugs

Indications